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Background: Prediabetes is an independent risk factor for cardiovascular diseases. Mean platelet volume (MPV) can
reflect platelet activity, and high MPV is associated with thrombogenic activation and an increased risk of
cardiovascular disease. In diabetic patients, MPV is higher when compared with normal subjects. However, the
relationship between MPV and prediabetes is poorly understood. The purpose of the present study was to compare
MPV in prediabetic and normoglycemic subjects, and to evaluate the relationship between MPV and fasting plasma
glucose (FPG) levels in these two groups.
Methods: We retrospectively studied 1876 Japanese subjects who had undergone health checks at Iida Municipal
Hospital. Age, sex, body mass index (BMI), blood pressure, medical history, smoking habits, alcohol intake, lipid
profiles, FPG levels, and MPV were evaluated. Subjects were categorized into four groups according to FPG: Q1
(70 mg/dL ≤ FPG < 90 mg/dL, n = 467), Q2 (90 mg/dL ≤ FPG < 95 mg/dl, n = 457), Q3 (95 mg/dL ≤ FPG < 100
mg/dL, n = 442), and Q4 (100 mg/dL ≤ FPG < 126 mg/dL, n = 512). Q1, Q2, and Q3 were defined as normal FPG
groups and Q4 was defined as prediabetic group.
Results: The MPV increased with the increasing FPG levels, in the following order: Q1 (9.89 ± 0.68 fl), Q2 (9.97 ± 0.69 fl),
Q3 (10.02 ± 0.72 fl), and Q4 (10.12 ± 0.69 fl). After adjusting for the confounding parameters, MPV of the prediabetic
group was higher than that in other groups (P < 0.001 for Q4 vs. Q1 and Q2, and P < 0.05 for Q4 vs. Q3). MPV in the
high-normal glucose group (Q3) was significantly higher than in the low-normal glucose group (Q1). MPV was
independently and positively associated with FPG, not only in prediabetic subjects but also in normal FPG subjects
(β = 0.020 and β = 0.006, respectively).
Conclusions: MPV in patients with prediabetes was higher than that in normal subjects, and was positively associated
with FPG levels in prediabetic and normal subjects.
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The criteria for determining prediabetes are generally
defined as impaired fasting glucose (IFG) levels, impaired
glucose tolerance (IGT), or both [1]. Prediabetes is a
preclinical stage in the hyperglycemia continuum where
subjects are at increased risk of developing diabetes in the
near future [2]. Individuals with prediabetes are at a high* Correspondence: masanori19810813@yahoo.co.jp
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distribution, and reproduction in any mediumrisk of not only developing diabetes but also of adverse
cardiovascular events (myocardial infarction, stroke, or
cardiovascular death) in the later life [3,4].
Platelets play an important role in the normal hemostasis;
the mean platelet volume (MPV) and an accurate measure
of the platelet size are considered markers and determi-
nants of platelet function. Larger platelets with higher MPV
are hemostatically more reactive and produce higher
amounts of the prothrombotic factor Thromboxane A2,
increasing a propensity to thrombosis [5].tral Ltd. This is an Open Access article distributed under the terms of the
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risk factor for thromboembolism [6], stroke, and myocar-
dial infarction [7,8]. In patients with diabetes, MPV was
higher compared with the normal glycemic controls; in
addition, it has been proposed that an increase in MPV
may play a role in the micro- and macro-vascular compli-
cations related to diabetes [9,10]. Furthermore, platelet ac-
tivity recovers with improved glycemic control [11].
Although several studies have reported a positive asso-
ciation between MPV and fasting plasma glucose (FPG)
levels in diabetes [9,12], few reports have addressed the
correlation between MPV and FPG in the general popula-
tion [13,14]. One article, involving elderly Italian subjects
(mean age, 72.9 years), reported a significant positive cor-
relation between MPV and FPG [13]. On the other hand, a
second article, involving a Korean population, showed a
significant negative correlation between MPV and FPG in
normal FPG subjects [14]. These opposing results indicate
that the correlation between MPV and FPG in non-
diabetic subjects is controversial. Moreover, there are few
studies regarding the correlation between MPV and FPG
in intermediate hyperglycemic subjects [14].
The aim of the present study was to determine the re-
lationship between MPV and prediabetes and to evaluate




We investigated 2177 Japanese subjects who visited the
health promotion center of Iida Municipal Hospital from
October 2011 to September 2012. Seventeen subjects
with abnormal platelet counts (< 100 and > 400 × 103/μL)
and 53 subjects who were taking antiplatelet medicines
(aspirin, ticlopidine, and clopidogrel) were excluded. We
excluded 198 diabetic subjects with the history of anti-
diabetic therapy, FPG > 125 mg/dL, or HbA1c > 6.4%
[15]. Moreover, we excluded three subjects who had ex-
tremely low FPG levels (< 70 mg/dL). Three male sub-
jects with hemoglobin levels below 13 mg/dL and 27
female subjects with hemoglobin levels below 12 mg/dL
were also excluded from the study because nutritional
anemias can cause reactive thrombocytosis and thus in-
crease MPV. The remaining 1876 subjects were included
in this study. Informed consent was obtained from all the
participating subjects.
The subjects were divided into four groups on the basis
of FPG levels. Using the diagnostic criterion of the
American Diabetes Association [16], after assigning the
IFG subjects to group Q4 (100 mg/dL ≤ FPG <
126 mg/dL, n = 512), FPG levels were categorized into the
following tertiles: Q1 (70 mg/dL ≤ FPG < 90 mg/dL,
n = 467), Q2 (90 mg/dL ≤ FPG < 95 mg/dL, n = 457), and
Q3 (95 mg/dL ≤ FPG < 100 mg/dL, n = 442).Blood samples were collected in the morning following
a fasting period of 12 hours. The venous blood samples
were mixed with dipotassium EDTA and tested within
30 minutes of collection to minimize variations due to
sample aging. MPV and platelets were measured using
an automatic blood counter (XE-5000, Sysmex Corp.,
Japan). Glucose, uric acid, and lipid profiles were deter-
mined by standard methods.
Following were the criteria for dyslipidemia: serum
LDL-cholesterol ≥ 140 mg/dL, HDL-cholesterol < 40
mg/dL, triglycerides ≥ 150 mg/dL, or having been trea-
ted for dyslipidemia. Hypertension was defined as sys-
tolic blood pressure ≥ 140 mmHg, diastolic blood
pressure ≥ 90 mmHg, or presently taking any medication
prescribed for hypertension. BMI was calculated as
weight (kg)/height (m2).
A questionnaire was used to obtain information
about familial medical history and the subjects’ life-
style, such as smoking habits and alcohol ingestion.
Familial history of diabetes was defined as having
one or more relatives (parent or sibling) with dia-
betes. Individuals who had smoked < 100 cigarettes
during their lifetime were considered nonsmokers,
those who had smoked ≥ 100 cigarettes and were cur-
rently not smoking were considered former smokers, and
those who had smoked ≥ 100 cigarettes and were cur-
rently smoking were considered current smokers. The
following criteria were defined for alcohol consump-
tion groups: drinking never or rarely (0–5 times/year),
occasionally (1–5 times/month), and regularly (1–7
times/week).Statistical analysis
Statistical analyses were performed using the SPSS
software version 15.0 (SPSS Inc. IL, USA). The clinical
characteristics of the four groups were compared using
one-way analysis of variance (ANOVA) for continuous
variables, whereas the chi-squared test was used to
compare the categorical parameters.
Pearson’s correlation coefficients were calculated to
evaluate the relationships between MPV and several
clinical variables [age, sex, blood pressure (systolic/dia-
stolic), BMI, uric acid, total cholesterol, HDL-cholesterol,
LDL-cholesterol, smoking, and alcohol ingestion]. The
distribution of triglycerides was skewed; hence, we
conducted Pearson’s linear correlation using log-
transformed values instead of the raw data. To assess
independent relationships between MPV and the clin-
ical variables, a multiple linear regression analysis was
performed. MPV of the four groups were analyzed
using ANCOVA test, considering confounding factors.
Data were expressed as mean ± standard deviation. P values
less than 0.05 were considered statistically significant.
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The characteristics of the 1876 subjects enrolled in this
study are displayed in Table 1. The MPV increased with
the increasing FPG levels. In addition, age, male/female
ratio, BMI, systolic blood pressure, diastolic blood pressure,
uric acid, lipid profiles, smoking status, and alcohol
ingestion differed in the four groups.
In all the groups (Q1–Q4), a significant correlation
was observed between MPV and FPG, sex, age, BMI, sys-
tolic blood pressure, diastolic blood pressure, and uric
acid (Table 2). In addition, not only in the prediabetic
group (Q4) but also in normal FPG groups (Q1–Q3),
MPV correlated with FPG. However, lipid profiles, smo-
king habits, and alcohol ingestion were not correlated
with MPV. After adjusting for these confounding factors
using multiple linear regression analysis, MPV was found
to be independently and positively associated with FPG,
not only in prediabetic subjects but also in the subjectsTable 1 Clinical and metabolic characteristics of study partici
Q1 Q2
(n=467) (n=455
FPG (mg/dl) 84.63±3.83 92.05±1
MPV (fl) 9.89±0.68 9.97±0.6
Count of platlets (104/μL) 21.38±5.80 21.61±4
Men (%) 38.8% 56.70%
Age (years) 51.40±11.52 51.99±11
BMI (kg/m2) 21.48±2.82 22.31±3
SBP (mmHg) 113.33±15.70 117.87±15
DBP (mmHg) 66.78±11.12 70.35±11
UA (mg/dl) 4.95±1.21 5.40±1.3
TC (mg/dl) 203.80±34.36 206.27±33
TG (mg/dl) 89.63±68.38 107.26±92
HDL-C (mg/dl) 66.94±15.61 63.20±14
LDL-C (mg/dl) 114.65±31.15 118.67±30
Hypertension (%) 12.0% 15.60%
Dyslipidemia (%) 34.7% 48.13%








never or rarely 39.6% 35.82%
Data are shown as the mean ± standard deviation and percentage (%).
P values were calculated using the ANOVA and X2-tests.
FPG, fasting plasma glucose; MPV, mean platelet volume; BMI, body mass index.
SBP, systolic blood pressure; DBP, diastolic blood pressure.
UA, uric acid; TC, total cholesterol; TG, triglyceride; LDL-C, LDL-cholesterol; HDL-C, Hwith normal FPG levels (Table 3). This correlation was
stronger in prediabetic subjects than in normal FPG
subjects (β = 0.020 and β = 0.006, respectively).
As shown in Figure 1, even after adjusting for the
confounding parameters, MPV in the prediabetic group
(Q4) was higher than in other groups. Moreover, MPV
of the high-normal glucose group (Q3) was higher than
that of the low-normal glucose group (Q1) even after
adjustments of the parameters.
Discussion
MPV is modified by various biosocial and lifestyle fac-
tors such as race, gender, age, blood pressure, smoking
habits, and alcohol consumption [17,18]. In a previous
study, MPV could be positively correlated with fasting
glucose levels in diabetic and prediabetic groups; how-
ever, the sample size was modest (50 diabetic subjects




9 10.02±0.72 10.12±0.69 <0.001
.46 21.37±4.81 21.38±4.96 0.869
63.1% 68.8% <0.001
.08 54.16±10.88 57.41±10.32 <0.001
.03 22.89±3.18 23.67±3.28 <0.001
.96 117.79±15.28 124.24±14.66 <0.001
.05 70.12±11.00 74.73±10.32 <0.001
6 5.51±1.31 5.75±1.33 <0.001
.28 206.83±32.77 210.20±33.62 0.028
.24 109.92±68.34 122.91±80.18 <0.001
.15 60.79±14.23 60.73±15.02 <0.001











Table 2 Correlations between mean platelet volumes and various parameters
MPV in total
subjects (Q1~Q4)





r P-values r P-values r P-values
FPG (mg/dl) 0.25 P<0.001 0.17 P<0.01 0.28 P<0.001
Sex 0.1064 P<0.001 0.1064 P<0.001 0.1064 P<0.001
Age (years) 0.08 P<0.001 0.07 P<0.05 0.03 NS
BMI (kg/m2) 0.06 P<0.05 0.04 NS 0 NS
SBP (mmHg) 0.09 P<0.001 0.09 P<0.001 0.08 NS
DBP (mmHg) 0.1 P<0.001 0.07 P<0.05 0.07 NS
Uremic Acid (mg/dl) 0.1 P<0.001 0.09 P<0.001 0.08 NS
TC (mg/dl) -0.01 NS 0.01 NS -0.01 NS
Log TG 0.01 NS 0.03 NS 0.03 NS
HDL-C (mg/dl) -0.02 NS -0.02 NS -0.01 NS
LDL-C (mg/dl) -0.01 NS 0.0041 NS 0.0934 NS
Hypertension 0.0586 P<0.05 0.0263 NS 0.0782 NS
Dyslipidemia 0.0121 NS 0.0040 NS 0.0782 NS
Familial hisory of diabetes 0.0424 NS 0.0229 NS 0.0106 NS
Smoking status 0.0233 NS 0.0233 NS 0.0233 NS
Alcohol ingestion 0.0026 NS 0.0004 NS 0.0012 NS
Coefficients (r) and P-values are calculated using the Pearson’s correlation model.
FPG, fasting plasma glucose; MPV, mean platelet volume; BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure.
UA, uremic acid; TC, total cholesterol; Log TG, log-transformed triglyceride; LDL-C, LDL-cholesterol; HDL-C, HDL-cholesterol; NS, not significant.
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et al. [13] showed that MPV values were associated with
FPG in Italian subjects. However, these subjects were
not entirely representative of the general population
because most of the subjects were elderly (mean age,
72.9 years), hypertensive (86%), hypercholesterolemic
(47%), and overweight or obese (46%).
In the present study, we investigated the relation of
MPV and FPG levels in general population using anTable 3 Multiple linear regression analyses conducted to asse
variables






FPG (mg/dl) 0.009 P<0.001 0.006
Sex 0.078 NS 0.073
Age (years) 0.002 P<0.05 0.003
BMI (kg/m2) 0.004 NS 0.003
SBP (mmHg) 0.001 NS 0.001
DBP (mmHg) 0.002 NS 0.002
UA (mg/dl) 0.021 NS 0.006
R2=0.33, adjusted R2= 0.30, P<0.001 R2=0.19, a
FPG, fasting plasma glucose; MPV, mean platelet volume; BMI, body mass index.
SBP, systolic blood pressure; DBP, diastolic blood pressure; UA, uric acid; NS, not sigadequate sample size, and observed that MPV in
prediabetic subjects was higher than that in normogly-
cemic subjects. Furthermore, MPV of the high-normal
glucose subjects was higher than that of the low-normal
glucose subjects. Moreover, we observed a positive cor-
relation between MPV and FPG levels, not only in the
prediabetic but also in the normoglycemic subjects,
independent from variable factors. We excluded subjects
with extremely low FPG levels (< 70 mg/dL); therefore,ss independent relationships between MPV and clinical






























Figure 1 MPV in different fasting plasma glucose groups in
noncdiabetic subjects. One asterisk means P < 0.05, two asterisks
mean P < 0.01. Model 1; adjusted for age and sex. Model 2; adjusted for
age, sex, systolic blood pressure, diastolic blood pressure, BMI, uremic
acid, total cholesterol, triglyceride, HDL-cholesterol, LDL-cholesterol,
smoking, and alcohol ingestion.
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curve at the low glucose levels. However, at least in
the physiological glycemic range, the correlation be-
tween MPV and FPG levels was confirmed. Unlike
our results, Kim et al. [14] reported a negative correl-
ation between MPV and FPG in Korean subjects with
normal glucose tolerance and intermittent hyperglycemia,
although intermediate hyperglycemia is associated with an
increased risk of cardiovascular diseases. In contrast, we
evaluated triglyceride and uric acid levels and alcohol con-
sumption as confounding factors and reported that
MPV can differ based on individual characteristics, in-
cluding lipid profiles, alcohol intake, genetics, race/
ethnicity, and different populations.
The definition of IFG is not consistent worldwide.
According to the American Diabetes Association (ADA)
criterion, IFG is defined as FPG levels of 100–125 mg/dL;
this threshold was lowered in 2003 for better prediction of
future diabete incidence [20]. Other organizations, inclu-
ding the European Diabetes Epidemiology Group (EDEG)
and the Japan Diabetes Society (JDS), have retained
the original diagnostic range for IFG at FPG levels of 110–
125 mg/dL [21,22]. In the present study, we adopted ADA
criterion, more strictly than EDEG and JDS criteria, in
order to distinguish prediabetic subjects from normogly-
cemic subjects more efficiently. These stringent criteria
ensured increased sample confidence in our study.
The term “prediabetes” has replaced the clinical
definitions known as borderline or chemical diabetes,
traditionally used to identify the individuals at high
risk of progression to overt diabetes. Prediabetes has been
linked to a modest increase in overall cardiovascular
events and has been associated with a higher risk of stroke
[4,23]. Moreover, it has been reported that in prediabetic
individuals, the von Willebrand factor levels, essential forplatelet aggregation and adhesion, is significantly higher
than in the controls, and Willebrand factor levels were
positively correlated with MPV in the prediabetic group
(r = 0.452, P = 0.001) [24]. In our study, MPV in the pre-
diabetic subjects (Q4) was significantly higher than those
in low-normal glucose group (Q1), middle-normal glucose
group (Q2), and high-normal glucose group (Q3). Our
results suggest that the subjects with prediabetes tend to
have increased MPV that could have contributed to an
increased risk of cardiovascular disease.
A study using a large multiethnic cohort has demon-
strated that the risk of cardiovascular events or death in
normoglycemic and prediabetic subjects increases progres-
sively with increasing FPG levels. A 1 mmol/l (18 mg/dl) in-
crease in FPG has been associated with a 17% increase in
the risk of future cardiovascular events or death [25]. Even
within the normoglycemic range, elevated cardiovascular
risk is strongly and independently associated with glucose
levels. Subjects with fasting glucose levels in the high-
normal range (95–99 mg/dL) have an increased cardiovas-
cular risk when compared with subjects in low-normal
range (< 80 mg/dL) [26]. In the present study, MPV in the
high-normal glucose group (Q3) was higher than that in
the low-normal glucose group (Q1). Although the under-
lying mechanism of higher MPV in Q3 subjects remains
unclear, it has been suggested that increased MPV may be
due to osmotic swelling as a result of hyperglycemia [27].
Another postulated mechanism from a study in mice
demonstrated that insulin induces megakaryocytes to
produce larger platelets [28].
Obesity is a risk factor of cardiovascular disorders, partly
due to increased oxidative stress and inflammation, which
are associated with increased reactive oxygen species
(ROS) production and decreased NO bioavailability. Re-
cently, Monteiro et al. [29] showed that metabolic abnor-
malities, as a consequence of high-fat diets, cause platelet
hyperaggregability involving enhanced intraplatelet ROS
production and decreased NO bioavailability. In mildly
hypertriglyceridemic subjects, n-3 polyunsaturated fatty
acids increased MPV values slightly [30]. Although we did
not measure dietary fat intake in our subjects, there is a
possibility that a high-fat diet increases MPV. In obese
subjects, MPV was positively correlated with BMI and a
positive correlation was also shown between weight loss
and reduction in MPV [31]. A higher BMI value was
strongly associated with higher insulin levels and insulin
resistance. In subjects with cardiovascular disease, MPV
was significantly elevated in those with insulin resistance
when compared to insulin-sensitive subjects [32]. How-
ever, there are few reports regarding the correlation
between MPV and insulin level in the general population.
Nonetheless, MPV was positively associated with insulin
level in polycystic ovary syndrome, which is related to
increased insulin levels and the incidence of obesity [33].
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influence platelet reactivity in obese patients.
There are several limitations to our study. It has been
shown that up to five percent of subjects with IFG
appear to have diabetes as per the results of the 2-hour
glucose tolerance tests [34,35]. True diabetic and predia-
betic groups are demarcated by glucose tolerance tests.
Therefore, some of the people in the prediabetic group
might have had diabetes. Second, Our study was retro-
spective and we did not determine the relationship
between MPV and the clinical events. Lastly, our present
study only included Japanese subjects, in which the
prevalence of obesity (BMI > 30) was < 3%, in contrast to
> 30% in Europeans and Americans [36]. Therefore, a
duplicate study with other populations is indispensable
to confirm our results.
Using a representative sample of Japanese adults, we
found that the prediabetic subjects had higher MPV
than the control individuals. Furthermore, MPV could
be positively and independently correlated with the FPG
levels, not only in the prediabetic subjects but also in
normoglycemic subjects, after correcting for confounding
variables.
Conclusions
We demonstrated that MPV in prediabetic subjects was
higher than that in controls. Moreover, even within the
normal range, subjects with high-normal FPG levels had
higher MPV than the individuals with low FPG levels. In
prediabetic and normoglycemic subjects, MPV showed
positive correlation with FPG levels.
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